The FDA has approved Heron Therapeutic's Cinvanti, an injectable drug for the prevention of chemotherapy-induced nausea and vomiting.

A Heron spokeswoman said in a statement Cinvanti marks a milestone because it does not contain polysorbate 80, which may cause allergic reactions.

About four million people a year receive chemotherapy, one of the most common therapies for cancer.

Cinvanti follows Heron's drug Sustol, another anti-nausea drug that received FDA approval in August 2016.

Heron is a commercial-stage company with drug programs addressing pain management and cancer.